ANR...had a bad result and got thoroughly trashed recently . A short spurt on Friday after more news on its IBS ( irritable bowel syndrome) work.
It has another iron in the fire with its anti obesity project but has made it known its on the hunt for another project.
Priced as a shell, and a cheap one at that ( $1.2m mcap),though it has $800k it may need capital at a later stage.
Biotech isn't my scene as far as shells go but it ticks the boxes and well suited to slot in as a replacement for NSB, which provided grocery money recently. I hold a small parcel in a rarely used account so its basically out of sight. Though, any weakness and i'll be wheeling in the trolley and any empty saucepans and buckets!!
